Is Retatrutide FDA Approved? TRIUMPH Results and the Approval Timeline

No. As of October 2026, retatrutide is not approved by the FDA, or by any other regulator, for any use. Eli Lilly's own FAQ, last updated September 2026, says it is investigational and "legally available only through Lilly's clinical trials"⁹. Lilly has not filed for approval yet. Its July 2026 announcement says it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027³.

What changed this year is the evidence, not the status. Four large phase 3 trials have now reported, and the headline trial, TRIUMPH-1, was published in the New England Journal of Medicine on September 29, 2026¹. That makes retatrutide one of the best-documented unapproved drugs in the category. It is still unapproved.

The short version

• •Status: investigational. No FDA approval, no label, no brand name announced⁹.
• •Filing: BLA planned for Q1 2027, for obesity, knee osteoarthritis pain and obstructive sleep apnea³.
• •Decision: not before the FDA's review clock runs. Under the FDA's standard goals, a Q1 2027 filing points to a decision in roughly early 2028, or late 2027 with priority review¹¹¹².
• •What is sold online today under the name is not the drug Lilly is testing. FDA says retatrutide cannot be used in compounding under federal law¹⁰.

What TRIUMPH-1 found

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and no diabetes, and randomized them to once-weekly retatrutide at 4 mg, 9 mg or 12 mg, or placebo, for 80 weeks¹⁸. It is registered as NCT05929066 and finished in April 2026⁸.

The headline number depends on how you count people who stopped the drug, and the two counts differ by more than three points:

• •Lilly's headline (efficacy estimand, everyone assumed to stay on drug): 28.3% average weight loss on 12 mg, 25.9% on 9 mg and 19.0% on 4 mg, versus 2.2% on placebo².
• •The NEJM primary analysis (treatment-regimen estimand, everyone randomized counted as assigned): 25.0% on 12 mg, 23.7% on 9 mg and 17.6% on 4 mg, versus 3.9% on placebo¹.

Both are real. The second is the more conservative one, and it is the figure the peer-reviewed paper leads with. In a blinded extension for participants with a starting BMI of 35 or more, weight loss on 12 mg reached 30.3% at 104 weeks on the efficacy count, or 29.9% on the treatment-regimen count².

The trial also tested two problems weight loss is supposed to help. In 574 participants with knee osteoarthritis, retatrutide lowered pain scores more than placebo, and in 243 with obstructive sleep apnea it cut breathing events per hour by roughly 32 to 34 on the higher doses, versus about 10 on placebo¹. Those two results are why Lilly's planned filing names knee osteoarthritis pain and sleep apnea alongside obesity³.

For scale: the 2023 phase 2 trial reported 24.2% at 48 weeks on 12 mg⁶. TRIUMPH-1 confirmed that effect in a population roughly seven times larger, over a longer run. The design of the whole program was published in advance⁷.

TRIUMPH-2 and TRIUMPH-3: diabetes and heart disease

These two trials matter because they test the people most likely to be prescribed the drug, and the results came in lower than TRIUMPH-1.

TRIUMPH-2 randomized 1,152 adults with obesity and type 2 diabetes⁴. On the peer-reviewed treatment-regimen count, weight loss at 80 weeks was 18.8% on 12 mg, 16.8% on 9 mg and 11.9% on 4 mg, versus 5.1% on placebo⁴. A1C fell by about 1.4 to 1.6 points from a starting average of 7.7%³. Lower weight loss in diabetes is the usual pattern for this drug class, and retatrutide followed it.

TRIUMPH-3 enrolled 1,949 adults with a BMI of 35 or more and established cardiovascular disease. Lilly reported up to 22.6% weight loss at 80 weeks on 12 mg, versus 3.2% on placebo³. That figure comes from a company announcement. The full paper has not been published yet.

The earlier TRIUMPH-4 trial, in obesity with knee osteoarthritis, reported up to 28.7% at 68 weeks in December 2025⁵.

The new side effect: dysesthesia

The finding that went the wrong way is a nerve-sensation side effect. Dysesthesia is an abnormal sense of touch, where ordinary contact can feel prickling, burning or painful. It was not flagged in the phase 2 trials. It showed up in every phase 3 readout, and it was generally more common on higher doses:

Lilly also reported the familiar GI pattern. In TRIUMPH-1, nausea ran 28.6% to 42.4% across doses versus 14.8% on placebo, and 11.3% of people on 12 mg stopped the drug for an adverse event, versus 4.9% on placebo². In TRIUMPH-2, the paper also reports more low blood pressure on retatrutide than on placebo⁴.

None of this is a reason to assume retatrutide will not be approved. It is the kind of signal an FDA review weighs, and it is part of why the label, if one comes, may not match the doses and claims circulating online now. Our retatrutide side effects guide covers the full safety record.

What happens between a BLA and a label

A BLA is the application. Approval is the FDA's decision on it, and the two are separated by a review clock the FDA publishes in advance.

For a new molecule like retatrutide, the FDA first takes about 60 days to decide whether the application is complete enough to file. Its goal is then to act within 10 months under standard review, or 6 months under priority review¹¹¹².

That gives a simple calendar. A Q1 2027 submission plus about 12 months points to early 2028 on a standard review. With priority review, about 8 months points to late 2027. Lilly has not said which pathway it expects. The FDA can also ask for more data, which resets the timeline.

Two other things are worth knowing:

• •The brand name comes later. Lilly has not announced one. Its September 2026 FAQ still uses only the generic name⁹. A brand name usually appears with the approval.
• •Lilly has not published a price. Its FAQ says only that the price will reflect "the overall value to the healthcare system"⁹. Every "retatrutide price" quoted today is for something other than the approved drug. Our retatrutide cost page shows how few sellers even post one.

Why "research retatrutide" is not this drug

Searches for retatrutide now run into a large gray market. A JAMA news report in October 2026 described a growing black market for retatrutide sold online¹³.

The FDA's position is direct. Its consumer page, current as of October 1, 2026, says retatrutide "cannot be used in compounding under federal law," that it has "not been found safe and effective for any condition," and that the agency has warned sellers whose products are falsely labeled "for research purposes" or "not for human consumption"¹⁰. Lilly's FAQ says anything sold outside its trials may contain the wrong ingredient, too much or too little of it, or contaminants⁹.

The risk is not theoretical. A case report published in October 2026 describes a woman in her mid-20s hospitalized with days of vomiting after four weekly injections of a product sold as retatrutide, given in a wellness setting by a non-medical "life coach"¹⁴.

A vial sold under the name is not an early version of the approved product. Nobody outside the trials can confirm what is in it. Our peptide regulatory tracker lists retatrutide on no federal compounding list, and our dosage calculator does the arithmetic without proposing a dose.

What you can be prescribed today instead

If the goal is the strongest approved option available now, that is tirzepatide, a dual GIP/GLP-1 agonist. Retatrutide adds a third receptor, glucagon. Our retatrutide vs tirzepatide comparison sets out the difference.

Tirzepatide is available as brand Zepbound or as a compounded version through telehealth. Prices vary more than the headlines suggest:

• •ShedRx lists compounded tirzepatide at $299 a month with no prepay; its "as low as $239" needs a year paid up front.
• •Willow prints $399 a month for tirzepatide on its open product pages, with the evaluation included.
• •SkinnyRx shows a $99 first month but no public price for month two.
• •Ro prescribes brand Zepbound and Lilly's oral Foundayo, with a membership billed on top of the drug.
• •Amazon One Medical prescribes only brand-name GLP-1s; uninsured, Foundayo is $149 a month there.

To compare more options, see our ranked tirzepatide providers and the lowest published tirzepatide prices.

Bottom line

Retatrutide is not FDA approved. As of October 2026, it has strong phase 3 data, two peer-reviewed phase 3 papers, a new dose-related nerve-sensation side effect, and a filing Lilly plans for Q1 2027. A decision would follow the FDA review clock, most plausibly in late 2027 or 2028. Until then, the only legal way to take it is inside a Lilly trial.